Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
Toripalimab is a programmed cell death protein 1 antibody.This is an open-label, single arm, multi-center exploratory study.The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and sorafenib in patients with advanced stage hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: Toripalimab|DRUG: Sorafenib
Objective response rate (ORR), The proportion of patients in this trial whose tumor is destroyed or significantly reduced by the treatment. The extent of the reduction is assessed by researchers based on the RECIST 1.1 standard., through study completion, an average of 1 year
Progression free survival (PFS), The length of time during and after the treatment, that a patient lives with the tumor but it does not get worse., through study completion, an average of 1 year|Disease Control Rate (DCR), The percentage of patients who have achieved complete response, partial response and stable disease after treatment., through study completion, an average of 1 year|Duration of relief (DOR), The length of time that a tumor continues to respond to treatment without the cancer growing or spreading., through study completion, an average of 1 year|Overall survival, Evaluated by patients' survival status, 10 year
The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and sorafenib in patients with advanced stage hepatocellular carcinoma.